Reference for the treatment time of avatrombopag (Su Kexin) in the treatment of thrombocytopenia

Avatrombopag is an oral thrombopoietin receptor agonist (TPO-RA), mainly used to treat chronic liver disease-related thrombocytopenia and idiopathic thrombocytopenic purpura (ITP) and other diseases. Its mechanism of action promotes the differentiation and maturation of megakaryocytes in the bone marrow by activating the thrombopoietin receptor, thereby effectively increasing the number of platelets and providing patients with the possibility of preoperative preparation or long-term maintenance treatment.

In terms of treatment duration, the use of avatrombopag is usually individualized based on the type of disease and platelet levels. For patients with chronic liver disease before undergoing invasive procedures or surgeries, the course of treatment is generally short. The medication is usually started 10 to 15 days before surgery, and can be discontinued when the platelet count reaches a safe range on the day of surgery. The main goal of such short-term treatment is to rapidly increase platelet levels and reduce the risk of surgical bleeding, rather than to maintain platelet numbers long-term.

Avatrombopag may be used as long-term maintenance treatment in patients with idiopathic thrombocytopenic purpura (ITP). Treatment typically begins with a fixed daily dose, with periodic dose adjustments based on platelet response, and lasts from weeks to months. During treatment, doctors will monitor the efficacy based on platelet count and adjust the dose up or down if necessary to maintain platelets within a safe range while reducing the risk of bleeding and adverse drug reactions.

It should be noted that the treatment time of avatrombopag should fully consider individual patient differences, such as age, liver function, previous medication history, and bleeding risk. During the treatment process, blood routine and related laboratory indicators should be reviewed regularly to evaluate efficacy and safety in a timely manner. Scientific and individualized treatment arrangements can not only ensure rapid recovery of platelet levels, but also reduce the risk of long-term medication, providing safe and effective treatment and management solutions for patients with thrombocytopenia.

Reference materials:https://www.drugs.com/